We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Dr. Josep Bassaganya-Riera is the Chairman and CEO of Landos Biopharma. He has 20 years of R&D, business development, fundraising, and entrepreneurial business experience leading biotech companies with innovative, large-scale translational programs in autoimmune and infectious diseases. He has published over 150 peer-reviewed publications, holds numerous patents, has founded 3 award-winning Companies (Landos Biopharma, BioTherapeutics and Pervida), raising over $78 million in non-dilutive and equity financing rounds, and was recently named 2017 Innovator of the Year. In 2018 he received the Research Excellence Award from the Biocomplexity Institute, and Pervida was named Technology Company of the year by the Chamber of Commerce.
In 2017, Josep founded Landos Biopharma, a company focused on developing new, oral treatments for patients with autoimmune diseases and closed a $10 million Series A round with Perceptive Advisors, a New York city-based $3.5 billion investment firm. It is advancing its robust pipeline of novel oral therapeutics for autoimmune diseases, a $100 billion market, through clinical testing and commercialization. Landos’ lead candidate, BT-11, has 2 open INDs and began a Phase 1 clinical trial in June 2018 for Crohn’s disease and Ulcerative Colitis with topline results anticipated by the end of 2018.
Josep is a captain of industry, innovator, serial entrepreneur, and thought leader in biotech. Dr. Bassaganya-Riera and his companies have been active members of a statewide group that supports the planning behind the Governor’s Virginia Bioscience Initiative and the BioHealth Capital Region. His work at the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) provided a better understanding of the immune system’s response to some of the most common diseases which represent a state of high unmet treatment need. This transformative computational modeling approach has been found to improve efficiency, decrease cost and reduce the time required to find treatments for debilitating diseases including autoimmune diseases and systemic chronic diseases such as obesity, heart disease, and diabetes. He has received funding from the National Institutes of Health and the Defense Threat Reduction Agency. Josep applies advanced informatics and computational modeling to accelerate the development of innovative technologies into medicines that are safer and more effective. Dr. Bassaganya-Riera holds a Ph.D. in immunology and nutrition from Iowa State University and a DVM from Autonomous University of Barcelona.
This speaker's sessions: